Meda AB (publ) AGM bulletin

At the annual general meeting (AGM) on May 9, 2012, of Meda AB (publ), corporate
ID 556427-2812, Box 906, SE-170 09 Solna, Sweden, declared a dividend of 2,25
SEK per share.

The AGM adopted balance sheets and income statements and discharged the members
of the board and the CEO from liability for the fiscal year 2011.

The board was elected according to the nomination committee´s revised proposal.
The nomination committee’s proposal for remuneration to the board and the
auditors was adopted.

The AGM authorized the board to make decisions on the issue of shares and
convertibles, and on buying and selling Meda shares. The AGM also resolved to
amend 9§ p.9 in the articles of association.

Details of the AGM resolutions are available at Meda’s head office at pipers väg
2A, Solna Sweden, or by calling +46 8 630 1900. They will be sent on request
free of charge to shareholders who provide an address.

The board
For further inquiries, please contact:

Anders Larnholt, Vice President Corporate Development & IR ph: 46 709-458 878
MEDA AB (publ) is a leading international specialty pharma company. Meda’s
products are sold in 120 countries worldwide and the company is represented by
its own organizations in 50 countries. The Meda share is listed under Large Cap
on the Nasdaq OMX Nordic Stock Exchange in Stockholm. Find out more, visit
www.meda.se.

Forward-looking Statements
This press release is not an offer to sell or a solicitation to buy shares in
Meda. This press release also contains certain forward-looking statements with
respect to certain future events and Meda’s potential financial performance.
These forward-looking statements can be identified by the fact that they do not
relate only to historical or current facts, and may sometimes include words such
as “may”, “will”, “seek”, “anticipate”, “expect”, “estimate”, “intend”, “plan”,
“forecast”, “believe” or other words of similar meaning. These forward looking
statements reflect the current expectations on future events of the management
at the time such statements are made, but are made subject to a number of risks
and uncertainties. In the event such risks or uncertainties materialize, Meda’s
results could be materially affected. The risks and uncertainties include, but
are not limited to, risks associated with the inherent uncertainty of
pharmaceutical research and product development, manufacturing and
commercialization, the impact of competitive products, patents, legal
challenges, government regulation and approval, Meda’s ability to secure new
products for commercialization and/or development and other risks and
uncertainties detailed from time to time in Meda AB’s interim or annual reports,
prospectuses or press releases. Listeners and readers are cautioned that no
forward-looking statement is a guarantee of future performance and that actual
result could differ materially from those contained in the forward-looking
statements. Meda does not intend, nor undertakes, to update any such forward
looking statements.